ClinicalTrials.gov record
Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women in North America
ClinicalTrials.gov ID: NCT01057901
Public ClinicalTrials.gov record NCT01057901. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
24 - Week Flibanserin 100mg for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women in Noth America
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The objective of this trial is to assess the safety and efficacy of 24-week course of flibanserin for the treatment of Hypoactive Sexual Desire Disorder (HSDD) in naturally postmenopausal women.
Study identification
- NCT ID
- NCT01057901
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 748 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 35 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 31, 2009
- Primary completion
- Dec 31, 2010
- Completion
- Dec 31, 2010
- Last update posted
- Jun 16, 2014
2010 – 2011
United States locations
- U.S. sites
- 84
- U.S. states
- 33
- U.S. cities
- 76
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 511.156.01059 Boehringer Ingelheim Investigational Site | Birmingham | Alabama | — | — |
| 511.156.01084 Boehringer Ingelheim Investigational Site | Tucson | Arizona | — | — |
| 511.156.01053 Boehringer Ingelheim Investigational Site | Tuscon | Arizona | — | — |
| 511.156.01069 Boehringer Ingelheim Investigational Site | Tuscon | Arizona | — | — |
| 511.156.01063 Boehringer Ingelheim Investigational Site | Little Rock | Arkansas | — | — |
| 511.156.01076 Boehringer Ingelheim Investigational Site | Little Rock | Arkansas | — | — |
| 511.156.01039 Boehringer Ingelheim Investigational Site | Anaheim | California | — | — |
| 511.156.01070 Boehringer Ingelheim Investigational Site | Berkeley | California | — | — |
| 511.156.01075 Boehringer Ingelheim Investigational Site | La Mesa | California | — | — |
| 511.156.01087 Boehringer Ingelheim Investigational Site | Los Angeles | California | — | — |
| 511.156.01064 Boehringer Ingelheim Investigational Site | Newport Beach | California | — | — |
| 511.156.01016 Boehringer Ingelheim Investigational Site | Oceanside | California | — | — |
| 511.156.01007 Boehringer Ingelheim Investigational Site | San Diego | California | — | — |
| 511.156.01038 Boehringer Ingelheim Investigational Site | San Diego | California | — | — |
| 511.156.01067 Boehringer Ingelheim Investigational Site | Colorado Springs | Colorado | — | — |
| 511.156.01036 Boehringer Ingelheim Investigational Site | Denver | Colorado | — | — |
| 511.156.01092 Boehringer Ingelheim Investigational Site | Fort Collins | Colorado | — | — |
| 511.156.01027 Boehringer Ingelheim Investigational Site | New London | Connecticut | — | — |
| 511.156.01022 Boehringer Ingelheim Investigational Site | Coral Gables | Florida | — | — |
| 511.156.01042 Boehringer Ingelheim Investigational Site | DeLand | Florida | — | — |
| 511.156.01047 Boehringer Ingelheim Investigational Site | Fort Lauderdale | Florida | — | — |
| 511.156.01051 Boehringer Ingelheim Investigational Site | Fort Lauderdale | Florida | — | — |
| 511.156.01011 Boehringer Ingelheim Investigational Site | Gainseville | Florida | — | — |
| 511.156.01078 Boehringer Ingelheim Investigational Site | Lake Worth | Florida | — | — |
| 511.156.01095 Boehringer Ingelheim Investigational Site | Orlando | Florida | — | — |
| 511.156.01046 Boehringer Ingelheim Investigational Site | Plantation | Florida | — | — |
| 511.156.01056 Boehringer Ingelheim Investigational Site | Columbus | Georgia | — | — |
| 511.156.01045 Boehringer Ingelheim Investigational Site | Marietta | Georgia | — | — |
| 511.156.01021 Boehringer Ingelheim Investigational Site | Roswell | Georgia | — | — |
| 511.156.01081 Boehringer Ingelheim Investigational Site | Savannah | Georgia | — | — |
| 511.156.01066 Boehringer Ingelheim Investigational Site | Boise | Idaho | — | — |
| 511.156.01025 Boehringer Ingelheim Investigational Site | Chicago | Illinois | — | — |
| 511.156.01028 Boehringer Ingelheim Investigational Site | Chicago | Illinois | — | — |
| 511.156.01089 Boehringer Ingelheim Investigational Site | South Bend | Indiana | — | — |
| 511.156.01010 Boehringer Ingelheim Investigational Site | Wichita | Kansas | — | — |
| 511.156.01008 Boehringer Ingelheim Investigational Site | Lexington | Kentucky | — | — |
| 511.156.01034 Boehringer Ingelheim Investigational Site | New Orleans | Louisiana | — | — |
| 511.156.01012 Boehringer Ingelheim Investigational Site | Shreveport | Louisiana | — | — |
| 511.156.01074 Boehringer Ingelheim Investigational Site | Boston | Massachusetts | — | — |
| 511.156.01079 Boehringer Ingelheim Investigational Site | Boston | Massachusetts | — | — |
| 511.156.01080 Boehringer Ingelheim Investigational Site | Haverhill | Massachusetts | — | — |
| 511.156.01006 Boehringer Ingelheim Investigational Site | Detroit | Michigan | — | — |
| 511.156.01086 Boehringer Ingelheim Investigational Site | Paw Paw | Michigan | — | — |
| 511.156.01005 Boehringer Ingelheim Investigational Site | Chaska | Minnesota | — | — |
| 511.156.01013 Boehringer Ingelheim Investigational Site | Olive Branch | Mississippi | — | — |
| 511.156.01088 Boehringer Ingelheim Investigational Site | Las Vegas | Nevada | — | — |
| 511.156.01001 Boehringer Ingelheim Investigational Site | New Brunswick | New Jersey | — | — |
| 511.156.01055 Boehringer Ingelheim Investigational Site | Plainsboro | New Jersey | — | — |
| 511.156.01037 Boehringer Ingelheim Investigational Site | Poughkeepsie | New York | — | — |
| 511.156.01031 Boehringer Ingelheim Investigational Site | Purchase | New York | — | — |
| 511.156.01009 Boehringer Ingelheim Investigational Site | The Bronx | New York | — | — |
| 511.156.01024 Boehringer Ingelheim Investigational Site | Cary | North Carolina | — | — |
| 511.156.01065 Boehringer Ingelheim Investigational Site | Charlotte | North Carolina | — | — |
| 511.156.01029 Boehringer Ingelheim Investigational Site | Greensboro | North Carolina | — | — |
| 511.156.01002 Boehringer Ingelheim Investigational Site | Raleigh | North Carolina | — | — |
| 511.156.01040 Boehringer Ingelheim Investigational Site | Statesville | North Carolina | — | — |
| 511.156.01026 Boehringer Ingelheim Investigational Site | Winston-Salem | North Carolina | — | — |
| 511.156.01093 Boehringer Ingelheim Investigational Site | Bismarck | North Dakota | — | — |
| 511.156.01052 Boehringer Ingelheim Investigational Site | Fargo | North Dakota | — | — |
| 511.156.01017 Boehringer Ingelheim Investigational Site | Beachwood | Ohio | — | — |
| 511.156.01032 Boehringer Ingelheim Investigational Site | Cincinnati | Ohio | — | — |
| 511.156.01033 Boehringer Ingelheim Investigational Site | Cincinnati | Ohio | — | — |
| 511.156.01068 Boehringer Ingelheim Investigational Site | Englewood | Ohio | — | — |
| 511.156.01077 Boehringer Ingelheim Investigational Site | Ashland | Oregon | — | — |
| 511.156.01072 Boehringer Ingelheim Investigational Site | Medford | Oregon | — | — |
| 511.156.01082 Boehringer Ingelheim Investigational Site | Philadelphia | Pennsylvania | — | — |
| 511.156.01094 Boehringer Ingelheim Investigational Site | West Reading | Pennsylvania | — | — |
| 511.156.01083 Boehringer Ingelheim Investigational Site | Warwick | Rhode Island | — | — |
| 511.156.01048 Boehringer Ingelheim Investigational Site | Anderson | South Carolina | — | — |
| 511.156.01058 Boehringer Ingelheim Investigational Site | Greenville | South Carolina | — | — |
| 511.156.01085 Boehringer Ingelheim Investigational Site | Watertown | South Dakota | — | — |
| 511.156.01073 Boehringer Ingelheim Investigational Site | Bristol | Tennessee | — | — |
| 511.156.01041 Boehringer Ingelheim Investigational Site | Chattanooga | Tennessee | — | — |
| 511.156.01035 Boehringer Ingelheim Investigational Site | Germantown | Tennessee | — | — |
| 511.156.01091 Boehringer Ingelheim Investigational Site | Jackson | Tennessee | — | — |
| 511.156.01060 Boehringer Ingelheim Investigational Site | Memphis | Tennessee | — | — |
| 511.156.01003 Boehringer Ingelheim Investigational Site | Austin | Texas | — | — |
| 511.156.01054 Boehringer Ingelheim Investigational Site | Dallas | Texas | — | — |
| 511.156.01050 Boehringer Ingelheim Investigational Site | Fort Worth | Texas | — | — |
| 511.156.01014 Boehringer Ingelheim Investigational Site | Houston | Texas | — | — |
| 511.156.01049 Boehringer Ingelheim Investigational Site | San Antonio | Texas | — | — |
| 511.156.01015 Boehringer Ingelheim Investigational Site | Richmond | Virginia | — | — |
| 511.156.01090 Boehringer Ingelheim Investigational Site | Richmond | Virginia | — | — |
| 511.156.01020 Boehringer Ingelheim Investigational Site | Seattle | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 16 non-U.S. sites.
Recently updated Sexual Dysfunctions, Psychological trials
Other public records listing Sexual Dysfunctions, Psychological. Sorted by last update posted; newest first. Not a recommendation.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01057901, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 16, 2014 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01057901 live on ClinicalTrials.gov.